Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) from a hold rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

A number of other research analysts have also recently issued reports on the stock. Guggenheim increased their target price on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a report on Friday, September 25th. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Wedbush restated an “outperform” rating and issued a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Damora Therapeutics, Inc. Common Stock presently has an average rating of “Buy” and a consensus target price of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of NASDAQ DMRA opened at $21.49 on Friday. Damora Therapeutics, Inc. Common Stock has a one year low of $4.95 and a one year high of $38.33. The firm has a market capitalization of $1.33 billion, a P/E ratio of -6.38 and a beta of 1.43. The company’s fifty day moving average is $23.53 and its two-hundred day moving average is $25.76.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. On average, sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was purchased at an average price of $20.23 per share, with a total value of $252,875.00. Following the purchase, the chief executive officer owned 512,500 shares of the company’s stock, valued at $10,367,875. This trade represents a 2.50% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DMRA. Squarepoint Ops LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $303,000. Arizona State Retirement System purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter valued at approximately $260,000. Seven Fleet Capital Management LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter valued at approximately $7,398,000. Finally, Braidwell LP acquired a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $42,146,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.